PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Otsuka Pharmaceuticals UK Limited
OP

Otsuka Pharmaceuticals UK Limited

Windsor
SME

Otsuka Pharmaceuticals UK Limited is dedicated to improving patient health through innovative products and solutions. The company focuses on addressing unresolved health issues and conducts research and development in both common and rare conditions.

otsuka.co.uk ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£411.9m
Live
13
Buyers
3
12m
£403.7m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts13 / 16
  • Top buyers3
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Otsuka Pharmaceuticals UK LimitedUpdated 06 Jul 2026

At a glance · for buyers and watchdogs

Otsuka Pharmaceuticals UK Limited has won £411.9m across 3 public-sector buyers, with 13 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
13 of 16Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Sectors served · 1/8
Central government✓
Local government✓
NHS & health✓
Housing✓
Utilities & energy✓
Financial services✓
Education✓
Defence✓
Services · 8
Samsca®Medication for treating hyponatremia. ↗Jinarc®Medication for treating autosomal dominant polycystic kidney disease. ↗Aripiprazole Otsuka 960mgMedication for treating schizophrenia and bipolar disorder. ↗Aripiprazole Otsuka 400mgMedication for treating schizophrenia and bipolar disorder. ↗Abilify® Oral SolutionMedication for treating schizophrenia and bipolar disorder. ↗Abilify® Orodispersible TabletsMedication for treating schizophrenia and bipolar disorder. ↗Abilify® TabletsMedication for treating schizophrenia and bipolar disorder. ↗Abilify® Solution for InjectionMedication for treating schizophrenia and bipolar disorder. ↗

Extracted automatically from otsuka.co.uk on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 13 live · 3 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Generic Pharmaceuticals - Wave 15c
NHS England—01 Jun 2026£403.7m2 yrspending
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)
NHS England3360000001 Jun 2024£0.023 yrsLive
NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals
NHS England3360000001 May 2023£6.1m2 yrsClosed
NHS National Generic Pharmaceuticals Wave 14a
NHS England3360000001 Feb 2023£2.1m2 yrsClosed
NHS National Generic Pharmaceuticals - Wave 15c
NHS England————Live
NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 1 May 2025
NHS England33600000———Live
NHS National Generic Pharmaceuticals Wave 15b
NHS England33600000———Live
NHS National Generic Pharmaceuticals Wave 14c
NHS England33600000———Live
NHS National Generic Pharmaceuticals Wave 14b
NHS England33600000———Live
NHS National Generic Pharmaceuticals Wave 14b
NHS England33600000———Live
Total live value £0.02 · mean award £25.7m1–10 of 16

Top buyers · 3 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
13 contracts
100%
since 2022
2
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
2 contracts
0%
3
eTenderwales
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire13 contracts
100%
Scotland2 contracts
0%
Wales1 contract
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Otsuka Pharmaceuticals UK Limited highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
OP
Otsuka Pharmaceuticals UK Limited
Yes£403.7m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 28 Aug 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
03615891
Status
Active
Type
Private limited
Incorporated
14 Aug 1998
Reg. office
2 Windsor Dials, Arthur Road, Windsor, SL4 1RS
SIC codes
46460
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • O'CONNOR, Annabel Barbara — director
    Appointed 17 Oct 2020
  • GYNNE, Ryan — director
    Appointed 03 Feb 2020
  • Otsuka Pharmaceutical Europe Ltd. — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors · significant influence or control

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
OTSUKA PHARMACEUTICALS (U.K.) LTD.
03615891 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.